Antengene Receives the US FDA’s IND Clearance of ATG-017 to Initiate P-I (ERASER) Trial for Advanced Solid Tumors
Shots:
- The US FDA has cleared an IND application to initiate the P-I (ERASER) trial evaluating the safety, PK & preliminary efficacy of ATG-017 + nivolumab for advanced solid tumors
- The results showed that the combination of an ERK1/2 inhibitor & an ICI worked synergistically to provide improved efficacy in preclinical ICI-resistant in vivo mice models
- ATG-017 is an oral, potent & selective small molecule ERK1/2 inhibitor & was approved in Australia & the US to enter clinical studies for advanced solid tumors or hematologic malignancies. The preclinical results showed the combination of ATG-017 & atezolizumab rendered "cold" tumors "hot" in an aggressive immune checkpoint-resistant murine cancer model
Ref: Antengene | Image: Antengene
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
